Raltegravir is the first approved integrase inhibitor for the treatment of HIV.The rapid mutation of the virus has led to chemo-resistant strains and there is a medical need to develop new drugs to overcome resistance.The development of novel integrase inhibitors with improved toxic profiles and alternate binding mechanisms are key to identifying new clinical candidates and avoiding known mutation pathways.Herein,we reported the design and synthesis of potent pyrimidone analogues as HIV integrase inhibitors.